Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Soquelitinib (CPI-818) in Atopic dermatitis . The expected timing is based on the latest available company guidance and may change.
4/9/24- Trial initiated. 12/18/24- Interim data. 1/13/25- Cohort 2 data. 5/8/25- Cohort 1-3 data reported. 6/4/25- Reported cohort 3 full data. 11/04/25:- Completed enrollment in extension cohort 4. 01/20/26:- Cohort 4 Ph1 AD data showed strong efficacy and safety; Ph2 AD trial initiation in Q1 2026. 03/12/26:- Cohort 4 Ph1 AD data positive; Ph2 AD trial initiated; China Ph1b/2 AD initial cohort results expected Late 2026. 04/21/26:- Final randomized blinded placebo-controlled Ph1 AD data at SID May 14 and May 16, 2026. 05/07/26:- Final randomized Ph1 AD data at SID May 13-16; Ph2 AD trial initiated; China Ph1b/2 initial results late 2026. 05/14/26:- Final Ph1 AD data at SID May 14-16. China Ph1b/2 initial results expected Late 2026. 08/06/26:- Final Ph1 AD data presented; SIERRA1 enrolling; China cohort 1 results expected Late 2026.
Verification
Confirm timing and program details against the company announcement or filing.